Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.

Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015 Sep; 86(9):996-1001.

View in: PubMed